Evidence map›Paper›PMID 37215489›Full record

ArticleTrends in analytical chemistry : TRAC2023

Mass spectrometry-based phosphoproteomics in clinical applications.

Xiaofeng Wu, Yi-Kai Liu, Anton B Iliuk, W Andy Tao

Abstract read
In one paragraph

Article in Trends in analytical chemistry : TRAC, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xiaofeng WuDepartment of Chemistry, Purdue University, West Lafayette, IN, USA.
Yi-Kai LiuDepartment of Biochemistry, Purdue University, West Lafayette, IN, USA.
Anton B IliukDepartment of Biochemistry, Purdue University, West Lafayette, IN, USA.
W Andy TaoDepartment of Chemistry, Purdue University, West Lafayette, IN, USA.

Funding

Dissecting signaling pathways and seeking EV phosphoproteins as novel biomarkers for Alzheimer's DiseaseRF1AG064250 · NIA · PURDUE UNIVERSITY · PI TAO, W. ANDY · 2020 to 2021
$1.7M
Development of non-invasive biomarker discovery and diagnostics approach for bladder cancer based on urine proteome and phosphoproteomeR44CA239845 · NCI · TYMORA ANALYTICAL OPERATIONS, LLC · PI ILIUK, ANTON · 2019 to 2021
$1.5M
Dissecting signaling pathways and seeking EV phosphoproteins as novel biomarkers for Alzheimer's DiseaseR01AG064250 · NIA · PURDUE UNIVERSITY · PI TAO, W. ANDY · 2024 to 2024
$386k
Development of non-invasive research and diagnostics platform for Alzheimer's disease based on plasma exosomesR43AG063589 · NIA · TYMORA ANALYTICAL OPERATIONS, LLC · PI ILIUK, ANTON · 2019 to 2019
$215k
NCI NIH HHS R44 CA239845NIA NIH HHS R01 AG064250NIA NIH HHS R43 AG063589NIA NIH HHS RF1 AG064250
6 · The paper itself

Abstract

Protein phosphorylation is an essential post-translational modification that regulates many aspects of cellular physiology, and dysregulation of pivotal phosphorylation events is often responsible for disease onset and progression. Clinical analysis on disease-relevant phosphoproteins, while quite challenging, provides unique information for precision medicine and targeted therapy. Among various approaches, mass spectrometry (MS)-centered characterization features discovery-driven, high-throughput and in-depth identification of phosphorylation events. This review highlights advances in sample preparation and instrument in MS-based phosphoproteomics and recent clinical applications. We emphasize the preeminent data-independent acquisition method in MS as one of the most promising future directions and biofluid-derived extracellular vesicles as an intriguing source of the phosphoproteome for liquid biopsy.

Indexed as

Data-independent acquisitionExtracellular vesicleMass spectrometryPhosphoproteomicsTissue/liquid biopsy

Identifiers

PMID37215489
PMCPMC10195102

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.